Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2298719rdf:typepubmed:Citationlld:pubmed
pubmed-article:2298719lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2298719lifeskim:mentionsumls-concept:C0001367lld:lifeskim
pubmed-article:2298719lifeskim:mentionsumls-concept:C0032134lld:lifeskim
pubmed-article:2298719pubmed:issue2lld:pubmed
pubmed-article:2298719pubmed:dateCreated1990-3-15lld:pubmed
pubmed-article:2298719pubmed:abstractTextDuring experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.lld:pubmed
pubmed-article:2298719pubmed:languageenglld:pubmed
pubmed-article:2298719pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2298719pubmed:citationSubsetIMlld:pubmed
pubmed-article:2298719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2298719pubmed:statusMEDLINElld:pubmed
pubmed-article:2298719pubmed:issn0733-2459lld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:LokiecFFlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:ChalopinJ MJMlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:PortierHHlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:BaillyFFlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:MoussonCClld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:RebibouJ MJMlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:ChavanetP YPYlld:pubmed
pubmed-article:2298719pubmed:authorpubmed-author:Waldner-Combe...lld:pubmed
pubmed-article:2298719pubmed:issnTypePrintlld:pubmed
pubmed-article:2298719pubmed:volume5lld:pubmed
pubmed-article:2298719pubmed:ownerNLMlld:pubmed
pubmed-article:2298719pubmed:authorsCompleteYlld:pubmed
pubmed-article:2298719pubmed:pagination68-9lld:pubmed
pubmed-article:2298719pubmed:dateRevised2005-7-26lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:meshHeadingpubmed-meshheading:2298719-...lld:pubmed
pubmed-article:2298719pubmed:year1990lld:pubmed
pubmed-article:2298719pubmed:articleTitleAcyclovir pharmacokinetics in plasmapheresis.lld:pubmed
pubmed-article:2298719pubmed:affiliationService des Maladies Infectieuses et Tropicales, Hopital du Bocage, Dijon, France.lld:pubmed
pubmed-article:2298719pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2298719lld:pubmed